Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.

@article{Cheng2012EfficacyAS,
  title={Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.},
  author={Ann-lii Cheng and Zhong-zhen Guan and Zhendong Chen and C. Andy Tsao and Shukui Qin and Jun Suk Kim and Tsai-Sheng Yang and Won Young Tak and Hongming Pan and Shiying Yu and Jianming Xu and Fang Fang and Jessie Zou and Giuseppe Lentini and Dimitris Voliotis and Yoon-Koo Kang},
  journal={European journal of cancer},
  year={2012},
  volume={48 10},
  pages={1452-65}
}
BACKGROUND The phase III Sorafenib Asia-Pacific (AP) trial-conducted in China, Taiwan and South Korea - confirmed that sorafenib improves overall survival (OS) and is safe for patients with advanced hepatocellular carcinoma (HCC). We performed a series of exploratory subset analyses to determine whether baseline status affected response to sorafenib. METHODS In the Sorafenib AP trial, 226 patients with well-preserved liver function (>95% Child-Pugh A) were randomised 2:1 to sorafenib 400mg… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

Newer treatments for advanced hepatocellular carcinoma

The Korean journal of internal medicine • 2014
View 4 Excerpts
Highly Influenced

Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2013
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of SHARP trial based on Barcelona Clinic Liver Cancer (BCLC) stage

J Bruix, JL Raoul, M Sherman
J Hepatol • 2009

Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial

L Bolondi, W Caspary, J Bennouna
Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January • 2008

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: a subanalysis from the SHARP trial

J Raoul, A Santoro, M Beaugrand
J Clin Oncol • 2008

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and prior anti-tumor therapy: a subanalysis from the SHARP trial

P Galle, J Blanc, Laethem Van
J Hepatol • 2008

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: a subanalysis from the SHARP trial

M Sherman, V Mazzaferro, D Amadori
J Clin Oncol • 2008

Similar Papers

Loading similar papers…